ImmuPharma (LON:IMM) Shares Up 28.8% - Time to Buy?

Key Points

• ImmuPharma's share price surged by 28.8% during mid-day trading, reaching a high of GBX 15.23 ($0.21) as approximately 44.7 million shares changed hands.
• The company reported a negative earnings per share (EPS) of GBX (0.38) and has a market cap of £69.86 million.
• ImmuPharma is a biopharmaceutical company focusing on peptide-based therapeutics targeting autoimmune diseases, with its lead program being Lupuzor™ for treating Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 28.8% on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). 44,749,293 shares changed hands during trading, an increase of 451% from the average session volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The firm has a market cap of £90.95 million, a PE ratio of -2,044.94 and a beta of 1.53. The business has a fifty day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.91.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.